Assembly Biosciences, Inc. (ASMB)
NASDAQ: ASMB · Real-Time Price · USD
24.64
+0.65 (2.71%)
At close: Aug 13, 2025, 4:00 PM
24.55
-0.20 (-0.81%)
Pre-market: Aug 14, 2025, 4:38 AM EDT
Assembly Biosciences Revenue
Assembly Biosciences had revenue of $9.63M in the quarter ending June 30, 2025, with 12.81% growth. This brings the company's revenue in the last twelve months to $33.25M, up 54.77% year-over-year. In the year 2024, Assembly Biosciences had annual revenue of $28.52M with 298.16% growth.
Revenue (ttm)
$33.25M
Revenue Growth
+54.77%
P/S Ratio
5.22
Revenue / Employee
$455,438
Employees
73
Market Cap
383.40M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ASMB News
- 5 days ago - Assembly Biosciences: Positive Data Of ABI-5366 Brings 2 Fall Program Catalysts - Seeking Alpha
- 6 days ago - Assembly Biosciences Announces Pricing of $175 Million in Equity Financings - GlobeNewsWire
- 6 days ago - Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes - GlobeNewsWire
- 7 days ago - Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates - GlobeNewsWire
- 7 days ago - Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus - GlobeNewsWire
- 19 days ago - Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop - GlobeNewsWire
- 6 weeks ago - Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179 - GlobeNewsWire
- 7 weeks ago - Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B - GlobeNewsWire